Pfizer, Inc. (PFE) is OLD Second National Bank of Aurora’s 10th Largest Position

OLD Second National Bank of Aurora boosted its position in shares of Pfizer, Inc. (NYSE:PFE) by 0.3% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 114,947 shares of the biopharmaceutical company’s stock after buying an additional 323 shares during the period. Pfizer comprises 1.8% of OLD Second National Bank of Aurora’s investment portfolio, making the stock its 10th largest position. OLD Second National Bank of Aurora’s holdings in Pfizer were worth $3,932,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Fusion Family Wealth LLC purchased a new stake in Pfizer during the fourth quarter worth about $109,000. Orrstown Financial Services Inc. increased its stake in Pfizer by 23.0% in the first quarter. Orrstown Financial Services Inc. now owns 3,275 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 612 shares during the period. Stanford Investment Group Inc. increased its stake in Pfizer by 11.8% in the fourth quarter. Stanford Investment Group Inc. now owns 4,329 shares of the biopharmaceutical company’s stock worth $141,000 after buying an additional 456 shares during the period. Cable Hill Partners LLC increased its stake in Pfizer by 6.0% in the first quarter. Cable Hill Partners LLC now owns 4,664 shares of the biopharmaceutical company’s stock worth $160,000 after buying an additional 265 shares during the period. Finally, D Orazio & Associates Inc. increased its stake in Pfizer by 0.5% in the fourth quarter. D Orazio & Associates Inc. now owns 5,223 shares of the biopharmaceutical company’s stock worth $170,000 after buying an additional 28 shares during the period. 70.80% of the stock is owned by hedge funds and other institutional investors.

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Shares of Pfizer, Inc. (NYSE:PFE) opened at 33.22 on Tuesday. The firm’s 50-day moving average price is $32.71 and its 200 day moving average price is $33.05. The firm has a market cap of $198.25 billion, a PE ratio of 27.96 and a beta of 1.02. Pfizer, Inc. has a 52 week low of $29.83 and a 52 week high of $37.39.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, May 2nd. The biopharmaceutical company reported $0.69 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.67 by $0.02. The company had revenue of $12.78 billion for the quarter, compared to the consensus estimate of $13.09 billion. Pfizer had a return on equity of 23.68% and a net margin of 13.76%. The firm’s revenue was down 1.7% compared to the same quarter last year. During the same period last year, the business posted $0.67 earnings per share. Equities analysts anticipate that Pfizer, Inc. will post $2.55 EPS for the current year.

The company also recently announced a quarterly dividend, which was paid on Thursday, June 1st. Investors of record on Friday, May 12th were given a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a yield of 3.85%. The ex-dividend date of this dividend was Wednesday, May 10th. Pfizer’s dividend payout ratio (DPR) is presently 108.48%.

WARNING: This news story was first posted by Ticker Report and is owned by of Ticker Report. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright legislation. The correct version of this news story can be accessed at https://www.tickerreport.com/banking-finance/2654243/pfizer-inc-pfe-is-old-second-national-bank-of-auroras-10th-largest-position.html.

Several equities research analysts have recently weighed in on PFE shares. Sanford C. Bernstein reaffirmed a “buy” rating and issued a $35.00 target price on shares of Pfizer in a research report on Friday, March 24th. Credit Suisse Group set a $38.00 target price on Pfizer and gave the stock a “buy” rating in a research report on Monday, March 13th. Barclays PLC set a $38.00 target price on Pfizer and gave the stock a “buy” rating in a research report on Thursday, March 16th. BMO Capital Markets reaffirmed a “hold” rating and issued a $33.00 target price on shares of Pfizer in a research report on Tuesday, March 21st. Finally, Vetr downgraded Pfizer from a “buy” rating to a “hold” rating and set a $34.97 target price for the company. in a research report on Thursday, February 23rd. One equities research analyst has rated the stock with a sell rating, eleven have assigned a hold rating and nine have assigned a buy rating to the stock. Pfizer has an average rating of “Hold” and a consensus price target of $37.32.

Pfizer Company Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer, Inc. (NYSE:PFE).

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
President Trump Hurting Tourism in the U.S.
President Trump Hurting Tourism in the U.S.
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.